Skip to main content

Table 4 Cross-reactivity analysis of ADA

From: B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera

Patient ID Age Anti-ADL (µg/ml) Control ID Age Anti-ADL (µg/ml)
438 29 <1.25 P* 48 <1.25
452 30 <1.25 F10 20 <1.25
485 64 <1.25 F22 25 <1.25
522 42 ≤1.25 F28 22 <1.25
587 41 <1.25 F31 45 <1.25
609 30 <1.25 F32 59 <1.25
623 57 <1.25 F33 25 <1.25
626 57 <1.25 F38 53 <1.25
638 32 <1.25 F41 19 <1.25
639 33 <1.25 F42 32 <1.25
648 4 <1.25 F43 31 <1.25
652 31 <1.25 F44 44 <1.25
660 26 <1.25 F45 36 <1.25
681 ? <1.25 F46 35 <1.25
694 13 <1.25 F47 33 <1.25
695 37 <1.25    
719 16 <1.25    
721 ? <1.25    
722 42 <1.25    
724 80 <1.25    
  1. IFX-treated patient sera positive for anti-IFX antibodies and untreated healthy control sera were analyzed in an ELISA system for anti-adalimumab (ADL) antibody detection